Evidence map›Paper›PMID 35341420›Full record

ArticleVascular2024

Eptifibatide bridging therapy for staged carotid artery stenting and cardiac surgery: Safety and feasibility.

M Travis Caton, Kazim H Narsinh, Amanda Baker, Matthew R Amans, Steven W Hetts, Joseph H Rapp, James C Ianuzzi, Elaine Tseng, Warren J Gasper, Daniel L Cooke

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vascular, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

M Travis CatonNeurointerventional Radiology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-1581-7702
Kazim H NarsinhNeurointerventional Radiology, University of California San Francisco, San Francisco, CA, USA.
Amanda BakerNeurointerventional Radiology, University of California San Francisco, San Francisco, CA, USA.
Matthew R AmansNeurointerventional Radiology, University of California San Francisco, San Francisco, CA, USA.
Steven W HettsNeurointerventional Radiology, University of California San Francisco, San Francisco, CA, USA.
Joseph H RappSan Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.
James C IanuzziSan Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.
Elaine TsengSan Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.
Warren J GasperSan Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.
Daniel L CookeNeurointerventional Radiology, University of California San Francisco, San Francisco, CA, USA.
San Francisco VA Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProphylactic carotid artery stenting (CAS) is an effective strategy to reduce perioperative stroke in patients with severe carotid stenosis who require cardiothoracic surgery (CTS). Staging both procedures (CAS-CTS) during a single hospitalization presents conflicting demands for antiplatelet therapy and the optimal pharmacologic strategy between procedures is not established. The purpose of this study is to present our initial experience with a "bridging" protocol for staged CAS-CTS.

methodsA retrospective review of staged CAS-CTS procedures at a single referral center was performed. All patients had multivessel coronary and/or valvular disease and severe carotid stenosis (>70%). Patients not previously on aspirin were also started on aspirin prior to surgery, followed by eptifibatide during CAS (intraprocedural bolus followed by post-procedural infusion which was continued until the morning of surgery). Pre- and perioperative (30 days) neurologic morbidity and mortality was the primary endpoint.

results11 CAS procedures were performed in 10 patients using the protocol. The median duration of eptifibatide bridge therapy was 36 h (range 24-288 h). There was one minor bleeding complication (1/11, 9.1%) and no major bleeding complications during the bridging and post-operative period. There was one post-operative, non-neurologic death and zero perioperative ischemic strokes.

conclusionsFor patients undergoing staged CAS-CTS, Eptifibatide bridging therapy is a viable temporary antiplatelet strategy with a favorable safety profile. This strategy enables a flexible range of time-intervals between procedures.

Indexed as

Carotid StenosisEptifibatideFeasibility StudiesPlatelet Aggregation InhibitorsStentsAgedAged, 80 and overAspirinCardiac Surgical ProceduresDrug Administration ScheduleFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsAspirinEptifibatidePlatelet Aggregation Inhibitorsantiplatelet therapycarotid-coronary revascularizationcarotid stentdual antiplateletendovascular surgeryEptifibatide

Identifiers

PMID35341420
PMCPMC11129521
OpenAlexW4221064645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.